Patients with locally advanced or metastatic differentiated thyroid cancer (DTC) that is radioactive iodine (RAI)- refractory and progressive have a poor prognosis due to the lack of effective treatment options. Several phase 2 trials have shown that some tyrosine kinase inhibitors with antiangiogenic effects are able to induce tumor responses in some patients, but there is yet no demonstration in a phase 3 trial that they may prolong progression free survival.
No takes yet. Share an insight, caveat, or question.
Martin Schlumberger (2014) studied this question.